Lantern Pharma Inc. (NASDAQ: LTRN) announced a significant milestone in its clinical development of LP-284, an investigational acylfulvene compound designed to target cancers with DNA repair deficiencies, at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York City, October 14–17, 2025. The presentation highlighted a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL), who had exhausted multiple advanced therapies including R-CHOP chemotherapy, radiation, CAR-T cell therapy, and a CD3xCD20 bispecific antibody. After just two 28-day cycles of LP-284 administered intravenously on days 1, 8, and 15, the patient achieved a complete metabolic response with non-avid lesions, validating the drug’s synthetic lethal mechanism. This outcome is particularly impactful given the patient’s poor prognosis following rapid disease progression after prior treatments. DLBCL, the most common aggressive non-Hodgkin’s lymphoma, affects around 200,000 people annually worldwide. Despite initial remission in many cases, relapse after advanced immunotherapies like CAR-T and bispecific antibodies is common, with median survival often measured in months and limited treatment options. An estimated 40,000 patients in the U.S. and EU alone progress post-CAR-T each year, with average treatment costs exceeding $500,000 per patient, underscoring a major unmet clinical and economic need. Panna Sharma, President and CEO of Lantern Pharma, called the data a pivotal inflection point, affirming the company’s AI-driven approach through its proprietary RADR® platform. LP-284, developed using artificial intelligence and machine learning, targets transcription-coupled nucleotide excision repair (TC-NER) pathways, making it effective regardless of TP53 mutation status or surface antigen expression. Preclinical data also show synergistic activity with rituximab and the ability to overcome ibrutinib resistance, supporting its potential as a combination therapy. The company’s ongoing Phase 1a dose-escalation trial (NCT06132503) continues to evaluate LP-284’s safety and efficacy in relapsed or refractory B-cell lymphomas and solid tumors. Early results indicate good tolerability with primarily Grade 1–2 adverse events and confirmed mechanism of action. Interest from biopharmaceutical companies and clinical investigators has surged, focusing on LP-284’s dual potential: as a monotherapy for post-immunotherapy patients and as a combination partner with FDA-approved agents like rituximab and bispecific antibodies. Beyond oncology, Lantern is advancing preclinical programs targeting autoimmune and inflammatory diseases, expanding LP-284’s therapeutic potential. The company strengthened its intellectual property position in July 2025 with a European Patent Office allowance for LP-284’s composition of matter, securing global protection through early 2039. This, combined with clinical validation and growing partnership interest, positions LP-284 for accelerated development and strategic collaborations. LP-284 has also received multiple FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas, further supporting its development path. The company remains focused on advancing its AI-powered drug discovery platform to deliver novel, high-impact therapies more efficiently and cost-effectively than traditional methods. While the results are promising, Lantern cautions that forward-looking statements—such as development timelines, trial outcomes, and commercial potential—involve risks, including funding limitations, uncertain clinical results, and regulatory hurdles. The company remains committed to transforming oncology through AI, with LP-284 representing a key step in addressing one of the most challenging areas in blood cancer treatment.